Tag: Metastatic cervical cancer drugs 2024

Home / Metastatic cervical cancer drugs 2024

Categories

Tisotumab vedotin-tftv is approved by the FDA for recurrent or metastatic cervical cancer

April 2024: Tisotumab vedotin-tftv (Tivdak, Seagen Inc. [now a part of Pfizer Inc.]) has received formal approval from the Food and Drug Administration for the treatment of recurrent or metastatic cer...
metastatic-cervical-cancer-drugs-2024

Scan the code